Skip to main content
. 2019 Mar 12;134(2):123–133. doi: 10.1182/blood-2019-02-895193

Figure 2.

Figure 2.

Confirmed clinical response. (A) ORR for all patients and by dose. (B) ORR for subgroups. aIndicates data representing dose-escalation cohort (n = 9) and expansion cohort (n = 22) combined. Bor, bortezomib; Car, carfilzomib; Len, lenalidomide; sCR, stringent complete response; VGPR, very good partial response.